Vir Biotechnology, Inc. (VIR)

11.70 +0.58 (+5.22%) USD  |  NASDAQ  |  Oct 09, 16:00
11.46 -0.24 (-2.05%) Pre-Market: 08:52
More

Vir Biotechnology Cash from Investing (Quarterly) : -197.14M for June 30, 2026

Cash from Investing (Quarterly) Chart

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2018. Start Trial.
Date Value
June 30, 2026 -197.14M
March 31, 2026 11.84M
December 31, 2025 86.65M
September 30, 2025 40.45M
June 30, 2025 56.46M
March 31, 2025 126.82M
December 31, 2024 140.74M
September 30, 2024 118.60M
June 30, 2024 211.61M
March 31, 2024 28.42M
December 31, 2023 -104.81M
September 30, 2023 -58.95M
June 30, 2023 230.32M
March 31, 2023 98.18M
December 31, 2022 -153.14M
September 30, 2022 -662.60M
Date Value
June 30, 2022 -272.33M
March 31, 2022 -105.39M
December 31, 2021 -377.58M
September 30, 2021 73.86M
June 30, 2021 75.38M
March 31, 2021 87.53M
December 31, 2020 60.71M
September 30, 2020 -185.38M
June 30, 2020 10.58M
March 31, 2020 104.22M
December 31, 2019 -73.77M
September 30, 2019
June 30, 2019
March 31, 2019
December 31, 2018 16.10M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Moderna, Inc. 329.00M
Vaxcyte, Inc. 147.72M
Caribou Biosciences, Inc. 18.94M
Arrowhead Pharmaceuticals, Inc. 43.68M
Oncolytics Biotech, Inc. 0.00

Cash from Investing (Quarterly) Related Metrics

Cash from Operations (Quarterly) 123.33M
Cash from Financing (Quarterly) 78.38M
Free Cash Flow -203.59M
Free Cash Flow Per Share (Quarterly) 0.7301
Free Cash Flow to Equity (Quarterly) 125.60M
Free Cash Flow to Firm (Quarterly) 123.29M
Free Cash Flow Yield -11.71%